TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma

Nanni, Patrizia; Giovanni, Carla De; Lollini, Pier‐Luigi; Nicoletti, Giordano; Prodi, Giorgio

doi:10.1007/bf00121199

Cited by 210 publications

(203 citation statements)

References 10 publications

Supporting

Mentioning

198

Contrasting

Order By: Relevance

“…The TS/A cell line [22][23][24] and the 4T1 cell line 25 were established from spontaneous, moderately differentiated mammary adenocarcinomas growing in BALB/c mice and were kindly provided by G. Forni (Immunogenetic and Histocompatibility Center, Turin, Italy) and F. R. Miller (Michigan Cancer Foundation, Detroit, Mich), respectively. When established as primary subcutaneous tumors, both of these adenocarcinomas metastasize primarily in the lungs.…”

Section: Mammary Tumor Modelsmentioning

confidence: 99%

“…When established as primary subcutaneous tumors, both of these adenocarcinomas metastasize primarily in the lungs. 22,25 Tumor cell cultures were maintained in RPMI 1640 medium supplemented with 10% fetal bovine sera, 2 mM L-glutamine, and 50 g/mL gentamicin. Before being injected i.d., tumor cells were detached from the plastic by a short incubation in trypsin-ethylenediaminetetraacetic acid solution.…”

Section: Mammary Tumor Modelsmentioning

confidence: 99%

See 1 more Smart Citation

Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism

Rakhmilevich

Janssen²,

Hao

et al. 2000

Cancer Gene Ther

View full text Add to dashboard Cite

In our previous studies using gene gun-mediated delivery of interleukin 12 (IL-12) cDNA in vivo, we observed T-cell-mediated regression of established murine tumors and demonstrated the induction of systemic immunity in test animals. In this study, we further characterized the antitumoral and anti-metastatic effect of this gene therapy approach by employing two murine metastatic mammary tumor models: the immunogenic TS/A adenocarcinoma and the weakly immunogenic 4T1 adenocarcinoma. In the TS/A model, gene transfer into the skin overlying an established intradermal tumor with an IL-12 cDNA expression vector resulted in complete tumor regression in 50% of mice followed by the development of immunological memory. In contrast, the growth of the intradermal 4T1 tumors was not affected by the IL-12 gene therapy protocol. However, this treatment resulted in a substantial reduction of spontaneous metastases in the lungs of 4T1 tumor-bearing mice and significantly prolonged their survival time. T cells were not required for this anti-metastatic effect, because it was also observed in nude mice and in mice depleted of CD4 ϩ and CD8 ϩ T cells. Tumor-draining lymph node cells obtained from 4T1 tumor-bearing mice treated with IL-12 cDNA exhibited increased natural killer (NK) activity and produced enhanced levels of interferon-␥ (IFN-␥) compared with similar mice treated with luciferase cDNA. In addition, in vivo depletion of NK cells or neutralization of IFN-␥ resulted in partial suppression of the anti-metastatic effect of IL-12 gene therapy, suggesting the involvement of both NK cells and IFN-␥ in this effect. Cancer Gene Therapy (2000) 1, 826 -838

show abstract

Section: Mammary Tumor Modelsmentioning

confidence: 99%

Section: Mammary Tumor Modelsmentioning

confidence: 99%

Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism

Rakhmilevich

Janssen²,

Hao

et al. 2000

Cancer Gene Ther

View full text Add to dashboard Cite

show abstract

“…TS /A is a tumor cell line established by P. Nanni ( Bologna, Italy) derived from a spontaneous mammary adenocarcinoma of the BALB /c strain 30 and kindly provided by P. Lollini (Bologna, Italy ). B16.F10 is a variant of B16, a melanoma cell line of C57BL /6 origin kindly provided by J. Galea-Lauri (London, UK ) .…”

Section: Cell Linesmentioning

confidence: 99%

The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status

et al. 2000

View full text Add to dashboard Cite

The expression of costimulatory molecules such as CD70 or CD80 by gene -modified tumor cells has been shown to enhance the antitumor immune response based mainly on T lymphocytes. However, most human tumors show defects of major histocompatibility complex ( MHC ) expression, preventing them from being recognized by MHC -restricted T cells. To investigate if coexpression of CD70 and CD80 costimulatory molecules induces comparable antitumor responses in low and high MHCexpressing tumor cells, we used two low immunogenic murine tumor models, the B16.F10 melanoma and the TS / A mammary adenocarcinoma cell lines expressing, respectively, low and high levels of MHC class I molecules. Transfection of both CD70 and CD80 genes resulted in an increased capacity of gene -modified tumor cells to costimulate in vitro the proliferation and cytokine production of optimally activated lymphoid cells. Coexpression of CD70 and CD80 by the two tumor cell lines, TS / A and B16.F10, resulted in both cases in partial regression of subcutaneous tumors. Immunochemical analysis and studies in nude mice showed that, even in the B16.F10 model, T cells had a significant role in the antitumor response induced by combining CD70 and CD80. However, rejection of the CD70 / CD80 -transfected tumor cells appeared more effective in the MHC class I high TS / A model, leading to a protection against parental tumor cells. B16.F10 and TS / A transfectants were then tested with fibroblasts genetically modified to secrete interleukin -12 ( IL -12 ) as a therapeutic vaccine in mice bearing parental tumors. In the two models tested, the injections of irradiated IL -12 and CD70 / CD80 gene -modified cells generated an antitumor response to established tumors leading to the slowing down of the tumor growth rate. Although the mechanisms remain to be defined, these findings suggest that the combination of several immuno -modulatory molecules could provide additional strategies for cancer immuno -gene therapy, even for MHC expression ± deficient tumors. Cancer Gene Therapy ( 2000 ) 7, 1543 ± 1556

show abstract

“…19 TS / A expresses major class I histocompatibility complex but not class II molecules, and does not stimulate a syngeneic antitumor response in vitro or in vivo. The minimal 100% tumor-inducing dose in syngeneic Balb -c mice is 4Â10 4 TS /A cells.…”

Section: Murine Tumor Model and Culture Conditionsmentioning

confidence: 98%

Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53

et al. 2001

View full text Add to dashboard Cite

The antitumor activity of a recombinant canarypox virus expressing wild type murine p53 ( ALVAC -p53 ) was investigated in two murine syngeneic tumors harboring an endogenous p53 mutation ( CMS 4 and TS / A ) . Direct intratumor injections of ALVAC -p53 in CMS 4 pre -established subcutaneous tumors induced total tumor regression in 66% of mice. Furthermore, 100% of the cured mice was protected against a contralateral subsequent challenge with the parental tumor cells. The intravenous treatment of experimental lung metastasis by ALVAC -p53 also induced significant tumor growth inhibition in both models. The antitumor effect of ALVAC -p53 was only observed in immunocompetent animals and was associated with the generation of a specific antitumor immune response. ALVAC -p53 induced the expression of a functional p53 wild type protein as demonstrated by up -regulation of p21 waf1 and induction of apoptosis. A vaccine strategy using intravenous or subcutaneous ALVAC -p53 / NYVAC -p53 prime boost protocol failed to induce CTL against p53 wild type used as target tumor antigen, and failed to protect mice against challenge with the mutated tumor cells. The mechanism of the curative and protective effects observed after direct intratumor injections results from the induction of a specific antitumor response directed against other antigens than p53. Our results suggest that the local induction of tumor apoptosis, combined with the adjuvant effect of ALVAC vector, enhances the immunogenicity of the intratumor environment and allows induction of specific antitumor immune response. Cancer Gene Therapy ( 2001 ) 8, 87 ± 98

show abstract

TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma

Cited by 210 publications

References 10 publications

Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism

Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism

The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status

Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53

Contact Info

Product

Resources

About